pioglitazone has been researched along with Compensatory Hyperinsulinemia in 47 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
Compensatory Hyperinsulinemia: A GLUCOSE-induced HYPERINSULINEMIA, a marker of insulin-resistant state. It is a mechanism to compensate for reduced sensitivity to insulin.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To thoroughly examine the mechanisms for insulin resistance in polycystic ovary syndrome (PCOS) and to evaluate the effects of pioglitazone treatment on insulin resistance, beta-cell function, LH secretion, and glucose metabolism." | 9.12 | Effect of pioglitazone on glucose metabolism and luteinizing hormone secretion in women with polycystic ovary syndrome. ( Andersen, M; Beck-Nielsen, H; Glintborg, D; Hagen, C; Henriksen, JE; Hermann, AP; Veldhuis, JD, 2006) |
| "To investigate the effectiveness and safety of pioglitazone (45 mg/day) on clinical and endocrine-metabolic features of polycystic ovary syndrome (PCOS), we studied 18 obese PCOS patients, classified as normoinsulinaemic (N-PCOS, n = 6) and hyperinsulinaemic (H-PCOS, n = 12) according to their insulin secretion." | 9.10 | Selective effects of pioglitazone on insulin and androgen abnormalities in normo- and hyperinsulinaemic obese patients with polycystic ovary syndrome. ( Ciampelli, M; Giuliani, M; Guido, M; Lanzone, A; Leoni, F; Perri, C; Romualdi, D, 2003) |
| "Evidence indicates that metformin and pioglitazone both improve insulin resistance and hirsutism among patient with polycystic ovarian syndrome (PCOS)." | 8.88 | A systematic review and meta-analysis of randomized controlled trials comparing pioglitazone versus metformin in the treatment of polycystic ovary syndrome. ( Du, Q; Han, P; Wang, YJ; Wu, B; Yang, S; Zhao, YY, 2012) |
| " Pioglitazone treatment (3 mg/kg body weight/d for 6 weeks), a peroxisome proliferator-activated receptor γ agonist, reversibly improved atherogenic dyslipidemia and insulin resistance and fully restored flow-mediated dilation with persistent benefits." | 7.77 | Rhesus macaques develop metabolic syndrome with reversible vascular dysfunction responsive to pioglitazone. ( Cheng, H; Ding, Y; Han, C; Hou, N; Huang, PL; Li, C; Li, K; Liu, N; Liu, Y; Mao, J; Raab, S; Sebokova, E; Shang, S; Song, Z; Wang, H; Wang, J; Xue, L; Zhang, H; Zhang, R; Zhang, X; Zhang, Y; Zheng, W; Zhu, T, 2011) |
| "Hyperinsulinemia is involved in the adrenal hyper-responsiveness to ACTH." | 6.73 | Pioglitazone reduces the adrenal androgen response to corticotropin-releasing factor without changes in ACTH release in hyperinsulinemic women with polycystic ovary syndrome. ( Costantini, B; Cristello, F; Draisci, G; Giuliani, M; Guido, M; Lanzone, A; Romualdi, D, 2007) |
| "Pioglitazone was also found to increase significantly the apo A1 levels in patients with hyperinsulinemia, but there was no significant increase in patients given both atorvastatin and pioglitazone." | 6.73 | Effect of pioglitazone and its combination with statins in coronary artery disease patients with hyperinsulinemia. ( Baxi, H; Chag, M; Chandarana, A; Goyal, R; Mehta, A; Naik, A; Parikh, K; Shah, K; Shah, U, 2007) |
| "To determine the role of hyperinsulinemia on follicle function in PCOS, we examined 24-h estradiol (E(2)) responses to recombinant human FSH (r-hFSH), 75 IU, before and during insulin infusion both before and after administration of pioglitazone (30 mg/d) in seven PCOS women." | 6.71 | Enhanced granulosa cell responsiveness to follicle-stimulating hormone during insulin infusion in women with polycystic ovary syndrome treated with pioglitazone. ( Chang, RJ; Coffler, MS; Dahan, MH; Malcom, PJ; Patel, K; Yoo, RY, 2003) |
| "Both insulin resistance and hyperinsulinemia are common in obesity." | 5.62 | Pioglitazone prevents obesity-related airway hyperreactivity and neuronal M ( Fryer, AD; Jacoby, DB; Nie, Z; Proskocil, BJ, 2021) |
| "Metformin treatment also improved hyperleptinemia, whereas pioglitazone was ineffective." | 5.36 | Metformin reduces body weight gain and improves glucose intolerance in high-fat diet-fed C57BL/6J mice. ( Hirasawa, Y; Ito, M; Kyuki, K; Matsui, Y; Sugiura, T; Toyoshi, T, 2010) |
| "Pioglitazone abolished the CCK-8-evoked hyperinsulinemia (P < 0." | 5.34 | Pioglitazone reverses insulin resistance and impaired CCK-stimulated pancreatic secretion in eNOS(-/-) mice: therapy for exocrine pancreatic disorders? ( DiMagno, MJ; Gangireddy, SR; Hao, Y; Lee, SH; Owyang, C; Reddy, RC, 2007) |
| "The reason why hyperinsulinemia produces hyperandrogenism and whether insulin action on the pituitary alters gonadotropin liberation remain unknown." | 5.33 | Endocrine-metabolic effects of the treatment with pioglitazone in obese patients with polycystic ovary syndrome. ( Garmes, HM; Tambascia, MA; Zantut-Wittmann, DE, 2005) |
| "One of the treatments for hyperinsulinemic hyperandrogenism in nonobese women is combined androgen receptor blockade (with flutamide; Flu), insulin sensitization (with metformin; Met) plus an estroprogestagen contraceptive." | 5.12 | Combined low-dose pioglitazone, flutamide, and metformin for women with androgen excess. ( de Zegher, F; del Rio, L; Enríquez, G; Ibáñez, L; López-Bermejo, A; Valls, C, 2007) |
| "To thoroughly examine the mechanisms for insulin resistance in polycystic ovary syndrome (PCOS) and to evaluate the effects of pioglitazone treatment on insulin resistance, beta-cell function, LH secretion, and glucose metabolism." | 5.12 | Effect of pioglitazone on glucose metabolism and luteinizing hormone secretion in women with polycystic ovary syndrome. ( Andersen, M; Beck-Nielsen, H; Glintborg, D; Hagen, C; Henriksen, JE; Hermann, AP; Veldhuis, JD, 2006) |
| "To investigate the effectiveness and safety of pioglitazone (45 mg/day) on clinical and endocrine-metabolic features of polycystic ovary syndrome (PCOS), we studied 18 obese PCOS patients, classified as normoinsulinaemic (N-PCOS, n = 6) and hyperinsulinaemic (H-PCOS, n = 12) according to their insulin secretion." | 5.10 | Selective effects of pioglitazone on insulin and androgen abnormalities in normo- and hyperinsulinaemic obese patients with polycystic ovary syndrome. ( Ciampelli, M; Giuliani, M; Guido, M; Lanzone, A; Leoni, F; Perri, C; Romualdi, D, 2003) |
| "Evidence indicates that metformin and pioglitazone both improve insulin resistance and hirsutism among patient with polycystic ovarian syndrome (PCOS)." | 4.88 | A systematic review and meta-analysis of randomized controlled trials comparing pioglitazone versus metformin in the treatment of polycystic ovary syndrome. ( Du, Q; Han, P; Wang, YJ; Wu, B; Yang, S; Zhao, YY, 2012) |
| "Our study indicates that combination therapy with canagliflozin and pioglitazone improves insulin sensitivity partly by preventing glucotoxicity and, at least partly, by attenuating pioglitazone-induced body weight gain in two different obese diabetic animal models." | 3.81 | Beneficial effects of canagliflozin in combination with pioglitazone on insulin sensitivity in rodent models of obese type 2 diabetes. ( Arakawa, K; Horai, Y; Kuriyama, C; Nakayama, K; Senbonmatsu, T; Shiotani, M; Taniuchi, N; Ueta, K; Watanabe, Y, 2015) |
| "The aim of this study was to observe clinical curative effects of combination application of dimethylbiguanide and pioglitazone and single application of pioglitazone in patients with polycystic ovarian syndrome (PCOS) complicated with insulin resistance (IR)." | 3.80 | Treatment of polycystic ovarian syndrome with insulin resistance by insulin-sensitizer. ( Hu, L; Hu, MH; Shen, H; Tian, L; Wu, QF, 2014) |
| " Pioglitazone treatment (3 mg/kg body weight/d for 6 weeks), a peroxisome proliferator-activated receptor γ agonist, reversibly improved atherogenic dyslipidemia and insulin resistance and fully restored flow-mediated dilation with persistent benefits." | 3.77 | Rhesus macaques develop metabolic syndrome with reversible vascular dysfunction responsive to pioglitazone. ( Cheng, H; Ding, Y; Han, C; Hou, N; Huang, PL; Li, C; Li, K; Liu, N; Liu, Y; Mao, J; Raab, S; Sebokova, E; Shang, S; Song, Z; Wang, H; Wang, J; Xue, L; Zhang, H; Zhang, R; Zhang, X; Zhang, Y; Zheng, W; Zhu, T, 2011) |
| " Pioglitazone treatment altered fat distribution, improved insulin sensitivity and normalized lipid and insulin level in rats on the high-fat diet." | 3.76 | Pioglitazone attenuates prostatic enlargement in diet-induced insulin-resistant rats by altering lipid distribution and hyperinsulinaemia. ( Jena, G; Ramarao, P; Vikram, A, 2010) |
| "To clarify the causal relationship between insulin resistance and the development of NASH, steatohepatitis was induced in obese diabetic Otsuka Long-Evans Tokushima Fatty (OLETF) and nondiabetic control Long-Evans Tokushima Otsuka (LETO) rats by feeding them a methionine and choline-deficient (MCD) diet." | 3.74 | Insulin resistance accelerates a dietary rat model of nonalcoholic steatohepatitis. ( Akahori, H; Kaneko, S; Kita, Y; Kurita, S; Matsuzawa, N; Misu, H; Nakanuma, Y; Ota, T; Sakurai, M; Takamura, T; Uno, M; Zen, Y, 2007) |
| "The present results suggest that pioglitazone improves not only insulin resistance, but also the dysfunctions in vascular control regulated by adrenergic and CGRPergic nerves in the hyperinsulinaemic state." | 3.74 | Pioglitazone opposes neurogenic vascular dysfunction associated with chronic hyperinsulinaemia. ( Egawa, T; Hanafusa, N; Kawasaki, H; Mio, M; Takatori, S; Yabumae, N; Zamami, Y, 2008) |
| " Pioglitazone, a thiazolidinedione derivative, sensitizes target tissues to insulin and decreases hyperglycemia and hyperinsulinemia in various insulin-resistant animals." | 3.70 | Pioglitazone attenuates basal and postprandial insulin concentrations and blood pressure in the spontaneously hypertensive rat. ( Gonzalez, R; Grinsell, JW; Lardinois, CK; Michaels, JR; Sare, JS; Starich, GH; Swislocki, A, 2000) |
| "These studies were designed to assess the effects of pioglitazone, a new oral antidiabetic agent that acts by improving insulin sensitivity, on blood pressure, plasma and tissue lipids, and insulin resistance in the Dahl salt-sensitive (Dahl-S) rat." | 3.69 | Malonyl coenzyme A and adiposity in the Dahl salt-sensitive rat: effects of pioglitazone. ( Colca, JR; Corkey, BE; Cunningham, BA; Holbert, RI; Kurowski, TG; Ruderman, NB; Saha, AK, 1996) |
| "Hyperinsulinemia is involved in the adrenal hyper-responsiveness to ACTH." | 2.73 | Pioglitazone reduces the adrenal androgen response to corticotropin-releasing factor without changes in ACTH release in hyperinsulinemic women with polycystic ovary syndrome. ( Costantini, B; Cristello, F; Draisci, G; Giuliani, M; Guido, M; Lanzone, A; Romualdi, D, 2007) |
| "Pioglitazone was also found to increase significantly the apo A1 levels in patients with hyperinsulinemia, but there was no significant increase in patients given both atorvastatin and pioglitazone." | 2.73 | Effect of pioglitazone and its combination with statins in coronary artery disease patients with hyperinsulinemia. ( Baxi, H; Chag, M; Chandarana, A; Goyal, R; Mehta, A; Naik, A; Parikh, K; Shah, K; Shah, U, 2007) |
| "Pioglitazone treatment resulted in a significant reduction in fasting levels of PI and SPI compared to those of the controls." | 2.73 | Reduced postprandial proinsulinaemia and 32-33 split proinsulinaemia after a mixed meal in type 2 diabetic patients following sensitization to insulin with pioglitazone. ( Al Majali, K; Bailey, CJ; Betteridge, DJ; Cooper, MB, 2008) |
| "To determine the role of hyperinsulinemia on follicle function in PCOS, we examined 24-h estradiol (E(2)) responses to recombinant human FSH (r-hFSH), 75 IU, before and during insulin infusion both before and after administration of pioglitazone (30 mg/d) in seven PCOS women." | 2.71 | Enhanced granulosa cell responsiveness to follicle-stimulating hormone during insulin infusion in women with polycystic ovary syndrome treated with pioglitazone. ( Chang, RJ; Coffler, MS; Dahan, MH; Malcom, PJ; Patel, K; Yoo, RY, 2003) |
| "Both insulin resistance and hyperinsulinemia are common in obesity." | 1.62 | Pioglitazone prevents obesity-related airway hyperreactivity and neuronal M ( Fryer, AD; Jacoby, DB; Nie, Z; Proskocil, BJ, 2021) |
| "It is the compensatory hyperinsulinemia rather than insulin resistance per se that causes blood pressure elevation." | 1.56 | Hyperinsulinemia rather than insulin resistance itself induces blood pressure elevation in high fat diet-fed rats. ( Chen, Y; Li, G; Pan, L; Shen, X; Tian, Y; Wang, H, 2020) |
| "Pioglitazone (PIO) is a member of the thiazolidinediones - a group of insulin-sensitizing drugs that are selective agonists of peroxisome proliferator-activated receptor gamma (PPARγ)." | 1.39 | Pioglitazone does not improve insulin signaling in mice with GH over-expression. ( Bartke, A; Gesing, A; Masternak, MM, 2013) |
| " VSMCs were treated in a dose-response manner with insulin (0, 1, 10, and 100 nM) for 20 min, and Akt and Erk phosphorylation were measured by Western blot analysis." | 1.38 | Potential role of insulin signaling on vascular smooth muscle cell migration, proliferation, and inflammation pathways. ( Cersosimo, E; Musi, N; Xu, X, 2012) |
| "Pioglitazone was administered in the diet at two concentrations (10 ppm and 100 ppm), the chemoprevention was initiated 12 days before carcinogenesis induction and lasted until the termination of the experiment." | 1.37 | Metabolic effects of pioglitazone in chemically-induced mammary carcinogenesis in rats. ( Ahlers, I; Ahlersová, E; Bojková, B; Garajová, M; Kajo, K; Kassayová, M; Kisková, T; Kubatka, P; Mokáň, M; Orendáš, P; Péč, M, 2011) |
| "Metformin treatment also improved hyperleptinemia, whereas pioglitazone was ineffective." | 1.36 | Metformin reduces body weight gain and improves glucose intolerance in high-fat diet-fed C57BL/6J mice. ( Hirasawa, Y; Ito, M; Kyuki, K; Matsui, Y; Sugiura, T; Toyoshi, T, 2010) |
| "Hyperinsulinemia is associated with enhanced MMP-9 serum levels, potentially facilitating monocyte migration to and infiltration of adipose tissue and the arterial wall, thereby contributing to the increased cardiovascular risk in obese, hyperinsulinemic patients." | 1.35 | Insulin facilitates monocyte migration: a possible link to tissue inflammation in insulin-resistance. ( Clemenz, M; Fleck, E; Graf, K; Kappert, K; Kintscher, U; Meyborg, H; Stawowy, P, 2008) |
| " These results provide a strong argument for using alogliptin in combination with pioglitazone." | 1.35 | The dipeptidyl peptidase-4 inhibitor alogliptin in combination with pioglitazone improves glycemic control, lipid profiles, and increases pancreatic insulin content in ob/ob mice. ( Asakawa, T; Kataoka, O; Moritoh, Y; Odaka, H; Takeuchi, K, 2009) |
| "Pioglitazone abolished the CCK-8-evoked hyperinsulinemia (P < 0." | 1.34 | Pioglitazone reverses insulin resistance and impaired CCK-stimulated pancreatic secretion in eNOS(-/-) mice: therapy for exocrine pancreatic disorders? ( DiMagno, MJ; Gangireddy, SR; Hao, Y; Lee, SH; Owyang, C; Reddy, RC, 2007) |
| "Hyperinsulinemia has been implicated in the development of diabetic nephropathy." | 1.34 | Thiazolidinediones provide better renoprotection than insulin in an obese, hypertensive type II diabetic rat model. ( Izuhara, Y; Kakuta, T; Miyata, T; Ohtomo, S; Takizawa, S; van Ypersele de Strihou, C; Yamada, N, 2007) |
| "The reason why hyperinsulinemia produces hyperandrogenism and whether insulin action on the pituitary alters gonadotropin liberation remain unknown." | 1.33 | Endocrine-metabolic effects of the treatment with pioglitazone in obese patients with polycystic ovary syndrome. ( Garmes, HM; Tambascia, MA; Zantut-Wittmann, DE, 2005) |
| "In untreated rats insulin sensitivity decreased by 46% over 3-6 h of elevated FFA, whereas it remained normal but with a 50% increase in FFA clearance in Pio-treated rats." | 1.31 | Prior thiazolidinedione treatment preserves insulin sensitivity in normal rats during acute fatty acid elevation: role of the liver. ( Cooney, GJ; Dzamko, N; Ellis, B; Frangioudakis, G; Furler, SM; Iglesias, MA; Kraegen, EW; Ye, JM, 2002) |
| "Insulin resistance is one of pathogenic factors for non-insulin-dependent diabetes mellitus (NIDDM)." | 1.28 | Effects of pioglitazone on glucose and lipid metabolism in Wistar fatty rats. ( Fujita, T; Ikeda, H; Shimura, Y; Sugiyama, Y; Taketomi, S, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (12.77) | 18.2507 |
| 2000's | 22 (46.81) | 29.6817 |
| 2010's | 17 (36.17) | 24.3611 |
| 2020's | 2 (4.26) | 2.80 |
| Authors | Studies |
|---|---|
| Wang, H | 2 |
| Tian, Y | 1 |
| Chen, Y | 1 |
| Shen, X | 1 |
| Pan, L | 1 |
| Li, G | 1 |
| Proskocil, BJ | 1 |
| Fryer, AD | 1 |
| Jacoby, DB | 1 |
| Nie, Z | 1 |
| Yin, QQ | 1 |
| Pei, JJ | 1 |
| Xu, S | 1 |
| Luo, DZ | 1 |
| Dong, SQ | 1 |
| Sun, MH | 1 |
| You, L | 1 |
| Sun, ZJ | 1 |
| Liu, XP | 1 |
| Gesing, A | 1 |
| Bartke, A | 1 |
| Masternak, MM | 1 |
| Ibáñez, L | 6 |
| Ong, KK | 1 |
| López-Bermejo, A | 5 |
| Dunger, DB | 1 |
| de Zegher, F | 6 |
| Straznicky, NE | 1 |
| Grima, MT | 1 |
| Sari, CI | 1 |
| Eikelis, N | 1 |
| Lambert, GW | 1 |
| Nestel, PJ | 1 |
| Karapanagiotidis, S | 1 |
| Wong, C | 1 |
| Richards, K | 1 |
| Marusic, P | 1 |
| Dixon, JB | 1 |
| Schlaich, MP | 1 |
| Lambert, EA | 1 |
| Hu, L | 1 |
| Shen, H | 1 |
| Wu, QF | 1 |
| Tian, L | 1 |
| Hu, MH | 1 |
| Watanabe, Y | 1 |
| Nakayama, K | 1 |
| Taniuchi, N | 1 |
| Horai, Y | 1 |
| Kuriyama, C | 1 |
| Ueta, K | 1 |
| Arakawa, K | 1 |
| Senbonmatsu, T | 1 |
| Shiotani, M | 1 |
| Díaz, M | 4 |
| Gallego-Escuredo, JM | 1 |
| Villarroya, F | 1 |
| Enríquez, G | 3 |
| del Río, L | 2 |
| Moritoh, Y | 1 |
| Takeuchi, K | 1 |
| Asakawa, T | 1 |
| Kataoka, O | 1 |
| Odaka, H | 2 |
| Coletta, DK | 1 |
| Sriwijitkamol, A | 1 |
| Wajcberg, E | 1 |
| Tantiwong, P | 1 |
| Li, M | 1 |
| Prentki, M | 1 |
| Madiraju, M | 1 |
| Jenkinson, CP | 1 |
| Cersosimo, E | 2 |
| Musi, N | 2 |
| Defronzo, RA | 1 |
| Matsui, Y | 1 |
| Hirasawa, Y | 1 |
| Sugiura, T | 1 |
| Toyoshi, T | 1 |
| Kyuki, K | 1 |
| Ito, M | 1 |
| Vikram, A | 2 |
| Jena, G | 2 |
| Ramarao, P | 1 |
| To, AW | 1 |
| Ribe, EM | 1 |
| Chuang, TT | 1 |
| Schroeder, JE | 1 |
| Lovestone, S | 1 |
| Bojková, B | 1 |
| Garajová, M | 1 |
| Péč, M | 1 |
| Kubatka, P | 1 |
| Kajo, K | 1 |
| Mokáň, M | 1 |
| Kassayová, M | 1 |
| Orendáš, P | 1 |
| Kisková, T | 1 |
| Ahlersová, E | 1 |
| Ahlers, I | 1 |
| Zhang, X | 1 |
| Zhang, R | 1 |
| Raab, S | 1 |
| Zheng, W | 1 |
| Wang, J | 1 |
| Liu, N | 1 |
| Zhu, T | 1 |
| Xue, L | 1 |
| Song, Z | 1 |
| Mao, J | 1 |
| Li, K | 1 |
| Zhang, H | 1 |
| Zhang, Y | 1 |
| Han, C | 1 |
| Ding, Y | 1 |
| Hou, N | 1 |
| Liu, Y | 1 |
| Shang, S | 1 |
| Li, C | 1 |
| Sebokova, E | 1 |
| Cheng, H | 1 |
| Huang, PL | 1 |
| Sebastiani, G | 1 |
| Sánchez-Infantes, D | 1 |
| Salvador, C | 1 |
| Xu, X | 1 |
| Du, Q | 1 |
| Wang, YJ | 1 |
| Yang, S | 1 |
| Wu, B | 1 |
| Han, P | 1 |
| Zhao, YY | 1 |
| Flores, MBS | 1 |
| Rocha, GZ | 1 |
| Damas-Souza, DM | 1 |
| Osório-Costa, F | 1 |
| Dias, MM | 1 |
| Ropelle, ER | 1 |
| Camargo, JA | 1 |
| de Carvalho, RB | 1 |
| Carvalho, HF | 1 |
| Saad, MJA | 1 |
| Carvalheira, JBC | 1 |
| Kotake, H | 1 |
| Ye, JM | 1 |
| Frangioudakis, G | 1 |
| Iglesias, MA | 1 |
| Furler, SM | 1 |
| Ellis, B | 1 |
| Dzamko, N | 1 |
| Cooney, GJ | 1 |
| Kraegen, EW | 1 |
| Romualdi, D | 2 |
| Guido, M | 2 |
| Ciampelli, M | 1 |
| Giuliani, M | 2 |
| Leoni, F | 1 |
| Perri, C | 1 |
| Lanzone, A | 2 |
| Suzuki, M | 1 |
| Coffler, MS | 1 |
| Patel, K | 1 |
| Dahan, MH | 1 |
| Yoo, RY | 1 |
| Malcom, PJ | 1 |
| Chang, RJ | 1 |
| Garmes, HM | 1 |
| Tambascia, MA | 1 |
| Zantut-Wittmann, DE | 1 |
| Glintborg, D | 1 |
| Hermann, AP | 1 |
| Andersen, M | 1 |
| Hagen, C | 1 |
| Beck-Nielsen, H | 1 |
| Veldhuis, JD | 1 |
| Henriksen, JE | 1 |
| Ota, T | 1 |
| Takamura, T | 1 |
| Kurita, S | 1 |
| Matsuzawa, N | 1 |
| Kita, Y | 1 |
| Uno, M | 1 |
| Akahori, H | 1 |
| Misu, H | 1 |
| Sakurai, M | 1 |
| Zen, Y | 1 |
| Nakanuma, Y | 1 |
| Kaneko, S | 1 |
| Valls, C | 2 |
| Draisci, G | 1 |
| Costantini, B | 1 |
| Cristello, F | 1 |
| Reddy, RC | 1 |
| Hao, Y | 1 |
| Lee, SH | 1 |
| Gangireddy, SR | 1 |
| Owyang, C | 1 |
| DiMagno, MJ | 1 |
| Mehta, A | 1 |
| Shah, U | 1 |
| Parikh, K | 1 |
| Chag, M | 1 |
| Baxi, H | 1 |
| Chandarana, A | 1 |
| Naik, A | 2 |
| Shah, K | 1 |
| Goyal, R | 1 |
| Ohtomo, S | 1 |
| Izuhara, Y | 1 |
| Takizawa, S | 1 |
| Yamada, N | 1 |
| Kakuta, T | 1 |
| van Ypersele de Strihou, C | 1 |
| Miyata, T | 1 |
| Cooper, MB | 1 |
| Al Majali, K | 1 |
| Bailey, CJ | 1 |
| Betteridge, DJ | 1 |
| Kappert, K | 1 |
| Meyborg, H | 1 |
| Clemenz, M | 1 |
| Graf, K | 1 |
| Fleck, E | 1 |
| Kintscher, U | 1 |
| Stawowy, P | 1 |
| Takatori, S | 1 |
| Zamami, Y | 1 |
| Yabumae, N | 1 |
| Hanafusa, N | 1 |
| Mio, M | 1 |
| Egawa, T | 1 |
| Kawasaki, H | 1 |
| Weinstein, SP | 1 |
| Holand, A | 1 |
| O'Boyle, E | 1 |
| Haber, RS | 1 |
| Kurowski, TG | 1 |
| Saha, AK | 1 |
| Cunningham, BA | 1 |
| Holbert, RI | 1 |
| Colca, JR | 1 |
| Corkey, BE | 1 |
| Ruderman, NB | 1 |
| Petrie, J | 1 |
| Small, M | 1 |
| Connell, J | 1 |
| Verma, S | 1 |
| Bhanot, S | 1 |
| Arikawa, E | 1 |
| Yao, L | 1 |
| McNeill, JH | 1 |
| Shibata, T | 1 |
| Matsui, K | 1 |
| Nagao, K | 1 |
| Shinkai, H | 1 |
| Yonemori, F | 1 |
| Wakitani, K | 1 |
| Grinsell, JW | 1 |
| Lardinois, CK | 1 |
| Swislocki, A | 1 |
| Gonzalez, R | 1 |
| Sare, JS | 1 |
| Michaels, JR | 1 |
| Starich, GH | 1 |
| Kadowaki, T | 1 |
| Sugiyama, Y | 1 |
| Taketomi, S | 1 |
| Shimura, Y | 1 |
| Ikeda, H | 1 |
| Fujita, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Mechanisms of Sympathetic Overactivity in the Metabolic Syndrome: Effects of Reversing Insulin Resistance by Drug Treatment[NCT00408850] | Phase 3 | 44 participants (Anticipated) | Interventional | 2008-11-30 | Recruiting | ||
| Molecular Mechanisms of Endothelial Dysfunction in Type 2 Diabetes Mellitus[NCT00816218] | Phase 4 | 39 participants (Actual) | Interventional | 2003-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for pioglitazone and Compensatory Hyperinsulinemia
| Article | Year |
|---|---|
A systematic review and meta-analysis of randomized controlled trials comparing pioglitazone versus metformin in the treatment of polycystic ovary syndrome.
Topics: Blood Glucose; Body Mass Index; Female; Hirsutism; Humans; Hyperinsulinism; Insulin Resistance; Metf | 2012 |
[Syndrome X].
Topics: Animals; Bezafibrate; Biguanides; Fatty Acids, Nonesterified; Humans; Hyperglycemia; Hyperinsulinism | 2002 |
[Hypertension and insulin resistance in obese type 2 diabetic Wistar fatty rat].
Topics: Animals; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Type 2; Disease Models, Anima | 2003 |
[Hypoglycemic agents to improve insulin resistance].
Topics: Adipocytes; Animals; Cell Differentiation; Chromans; Diabetes Mellitus, Type 2; Disease Models, Anim | 2000 |
13 trials available for pioglitazone and Compensatory Hyperinsulinemia
| Article | Year |
|---|---|
A randomized controlled trial of the effects of pioglitazone treatment on sympathetic nervous system activity and cardiovascular function in obese subjects with metabolic syndrome.
Topics: Blood Pressure; Diastole; Double-Blind Method; Echocardiography, Doppler; Endothelium, Vascular; Fem | 2014 |
Effects of ethinylestradiol-cyproterone acetate vs. pioglitazone-flutamide-metformin on plasma FGF21 levels in adolescent girls with androgen excess.
Topics: Adolescent; Cyproterone Acetate; Drug Combinations; Ethinyl Estradiol; Female; Fibroblast Growth Fac | 2016 |
Low-dose pioglitazone and low-dose flutamide added to metformin and oestro-progestagens for hyperinsulinaemic women with androgen excess: add-on benefits disclosed by a randomized double-placebo study over 24 months.
Topics: Adolescent; Androgen Antagonists; Androgens; Cross-Over Studies; Double-Blind Method; Drug Therapy, | 2009 |
Pioglitazone stimulates AMP-activated protein kinase signalling and increases the expression of genes involved in adiponectin signalling, mitochondrial function and fat oxidation in human skeletal muscle in vivo: a randomised trial.
Topics: Adiponectin; AMP-Activated Protein Kinases; Blood Glucose; Diabetes Mellitus, Type 2; Diet, Diabetic | 2009 |
Treatment of androgen excess in adolescent girls: ethinylestradiol-cyproteroneacetate versus low-dose pioglitazone-flutamide-metformin.
Topics: Abdominal Fat; Adolescent; Androgen Antagonists; Body Composition; Cyproterone Acetate; Drug Combina | 2011 |
Selective effects of pioglitazone on insulin and androgen abnormalities in normo- and hyperinsulinaemic obese patients with polycystic ovary syndrome.
Topics: 17-alpha-Hydroxyprogesterone; Acne Vulgaris; Adolescent; Adult; Androgens; Androstenedione; Body Con | 2003 |
Enhanced granulosa cell responsiveness to follicle-stimulating hormone during insulin infusion in women with polycystic ovary syndrome treated with pioglitazone.
Topics: Adult; Case-Control Studies; Dose-Response Relationship, Drug; Estradiol; Female; Follicle Stimulati | 2003 |
Effect of pioglitazone on glucose metabolism and luteinizing hormone secretion in women with polycystic ovary syndrome.
Topics: Adult; Blood Glucose; Double-Blind Method; Fasting; Female; Glucose Clamp Technique; Hormones; Human | 2006 |
Combined low-dose pioglitazone, flutamide, and metformin for women with androgen excess.
Topics: Adipose Tissue; Adolescent; Adult; Androgen Antagonists; Body Composition; Body Mass Index; Carotid | 2007 |
Pioglitazone reduces the adrenal androgen response to corticotropin-releasing factor without changes in ACTH release in hyperinsulinemic women with polycystic ovary syndrome.
Topics: Adolescent; Adrenal Glands; Adrenocorticotropic Hormone; Adult; Androgens; Corticotropin-Releasing H | 2007 |
Effect of pioglitazone and its combination with statins in coronary artery disease patients with hyperinsulinemia.
Topics: Apolipoprotein A-I; Apolipoproteins B; Atorvastatin; Blood Glucose; Body Mass Index; Cholesterol, HD | 2007 |
Reduced postprandial proinsulinaemia and 32-33 split proinsulinaemia after a mixed meal in type 2 diabetic patients following sensitization to insulin with pioglitazone.
Topics: Adult; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glyburide; Humans; Hyp | 2008 |
Pioglitazone (7.5 mg/day) added to flutamide-metformin in women with androgen excess: additional increments of visfatin and high molecular weight adiponectin.
Topics: Adiponectin; Adolescent; Adult; Double-Blind Method; Female; Flutamide; Humans; Hyperandrogenism; Hy | 2008 |
30 other studies available for pioglitazone and Compensatory Hyperinsulinemia
| Article | Year |
|---|---|
Hyperinsulinemia rather than insulin resistance itself induces blood pressure elevation in high fat diet-fed rats.
Topics: Animals; Blood Glucose; Blood Pressure; Diabetes Mellitus, Experimental; Diet, High-Fat; Hyperinsuli | 2020 |
Pioglitazone prevents obesity-related airway hyperreactivity and neuronal M
Topics: Animals; Bronchial Hyperreactivity; Diet, High-Fat; Hyperinsulinism; Hypoglycemic Agents; Insulin; M | 2021 |
Pioglitazone improves cognitive function via increasing insulin sensitivity and strengthening antioxidant defense system in fructose-drinking insulin resistance rats.
Topics: Analysis of Variance; Animals; Brain Diseases; Fructose; Hyperinsulinism; Insulin; Insulin Resistanc | 2013 |
Pioglitazone does not improve insulin signaling in mice with GH over-expression.
Topics: Animals; Blood Glucose; Disease Models, Animal; Growth Hormone; Hyperinsulinism; Hypoglycemic Agents | 2013 |
Hyperinsulinaemic androgen excess in adolescent girls.
Topics: Adolescent; Androgens; Drug Therapy, Combination; Dyslipidemias; Female; Flutamide; Hirsutism; Human | 2014 |
Treatment of polycystic ovarian syndrome with insulin resistance by insulin-sensitizer.
Topics: Adolescent; Adult; Blood Glucose; Body Mass Index; C-Reactive Protein; Cholesterol, HDL; Cholesterol | 2014 |
Beneficial effects of canagliflozin in combination with pioglitazone on insulin sensitivity in rodent models of obese type 2 diabetes.
Topics: Adipose Tissue; Animals; Body Weight; Canagliflozin; Cells, Cultured; Diabetes Mellitus, Experimenta | 2015 |
The dipeptidyl peptidase-4 inhibitor alogliptin in combination with pioglitazone improves glycemic control, lipid profiles, and increases pancreatic insulin content in ob/ob mice.
Topics: Animals; Blood Glucose; Body Weight; Dipeptidyl-Peptidase IV Inhibitors; Drug Combinations; Eating; | 2009 |
Metformin reduces body weight gain and improves glucose intolerance in high-fat diet-fed C57BL/6J mice.
Topics: Animals; Blood Glucose; Body Weight; Dietary Fats; Energy Intake; Glucagon-Like Peptide 1; Glucose I | 2010 |
S961, an insulin receptor antagonist causes hyperinsulinemia, insulin-resistance and depletion of energy stores in rats.
Topics: Animals; Cell Line; Glucose; Glucose Tolerance Test; Hyperglycemia; Hyperinsulinism; Hypoglycemic Ag | 2010 |
Pioglitazone attenuates prostatic enlargement in diet-induced insulin-resistant rats by altering lipid distribution and hyperinsulinaemia.
Topics: Animals; Apoptosis; Castration; Cell Proliferation; Dietary Fats; Disease Models, Animal; Glucose To | 2010 |
The ε3 and ε4 alleles of human APOE differentially affect tau phosphorylation in hyperinsulinemic and pioglitazone treated mice.
Topics: Alleles; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Apolipoproteins E; Diabetes | 2011 |
Metabolic effects of pioglitazone in chemically-induced mammary carcinogenesis in rats.
Topics: Animals; Corticosterone; Female; Glycogen; Heart; Hyperglycemia; Hyperinsulinism; Lipid Peroxidation | 2011 |
Rhesus macaques develop metabolic syndrome with reversible vascular dysfunction responsive to pioglitazone.
Topics: Animals; Blood Vessels; Disease Models, Animal; Disease Progression; Dyslipidemias; Hyperinsulinism; | 2011 |
Potential role of insulin signaling on vascular smooth muscle cell migration, proliferation, and inflammation pathways.
Topics: Cell Communication; Cell Movement; Cell Proliferation; Cells, Cultured; Dose-Response Relationship, | 2012 |
RETRACTED: Obesity-induced increase in tumor necrosis factor-α leads to development of colon cancer in mice.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Apoptosis; Azoxymethane; Blotting, Western; | 2012 |
Prior thiazolidinedione treatment preserves insulin sensitivity in normal rats during acute fatty acid elevation: role of the liver.
Topics: Acyl Coenzyme A; Adiponectin; Animals; Blood Glucose; Fat Emulsions, Intravenous; Fatty Acids, Nones | 2002 |
Endocrine-metabolic effects of the treatment with pioglitazone in obese patients with polycystic ovary syndrome.
Topics: Adolescent; Adult; Female; Hormone Antagonists; Humans; Hyperandrogenism; Hyperinsulinism; Obesity; | 2005 |
Insulin resistance accelerates a dietary rat model of nonalcoholic steatohepatitis.
Topics: Animal Feed; Animals; Choline; Collagen Type I; Collagen Type I, alpha 1 Chain; Diabetes Mellitus, T | 2007 |
Pioglitazone reverses insulin resistance and impaired CCK-stimulated pancreatic secretion in eNOS(-/-) mice: therapy for exocrine pancreatic disorders?
Topics: Animals; Gene Expression; Hyperinsulinism; Insulin; Insulin Receptor Substrate Proteins; Insulin Res | 2007 |
Thiazolidinediones provide better renoprotection than insulin in an obese, hypertensive type II diabetic rat model.
Topics: Animals; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Models, Animal; Glycation End Pr | 2007 |
Insulin facilitates monocyte migration: a possible link to tissue inflammation in insulin-resistance.
Topics: Animals; C-Peptide; Cell Line; Cell Movement; Chemotaxis, Leukocyte; Diet; Dietary Fats; Endothelium | 2008 |
Pioglitazone opposes neurogenic vascular dysfunction associated with chronic hyperinsulinaemia.
Topics: Administration, Oral; Angiotensin II; Animals; Blood Glucose; Blood Pressure; Chronic Disease; Disea | 2008 |
Effects of thiazolidinediones on glucocorticoid-induced insulin resistance and GLUT4 glucose transporter expression in rat skeletal muscle.
Topics: Animals; Benzopyrans; Blood Glucose; Deoxyglucose; Dexamethasone; Glucocorticoids; Glucose Transport | 1993 |
Malonyl coenzyme A and adiposity in the Dahl salt-sensitive rat: effects of pioglitazone.
Topics: Adipose Tissue; Animals; Blood Glucose; Blood Pressure; Dietary Carbohydrates; Dietary Fats; Hyperin | 1996 |
"Glitazones", a prospect for non-insulin-dependent diabetes.
Topics: Chromans; Diabetes Mellitus, Type 2; Humans; Hyperinsulinism; Hypoglycemic Agents; Insulin Resistanc | 1997 |
Direct vasodepressor effects of pioglitazone in spontaneously hypertensive rats.
Topics: Animals; Arginine Vasopressin; Drug Evaluation, Preclinical; Hyperinsulinism; Hypertension; Hypoglyc | 1998 |
Pharmacological profiles of a novel oral antidiabetic agent, JTT-501, an isoxazolidinedione derivative.
Topics: 3T3 Cells; Administration, Oral; Animals; Blood Glucose; Cell Differentiation; Chromans; Diabetes Me | 1999 |
Pioglitazone attenuates basal and postprandial insulin concentrations and blood pressure in the spontaneously hypertensive rat.
Topics: Animals; Area Under Curve; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Gl | 2000 |
Effects of pioglitazone on glucose and lipid metabolism in Wistar fatty rats.
Topics: Adipose Tissue; Animals; Diabetes Mellitus; Diabetes Mellitus, Type 2; Glucose; Glucose Tolerance Te | 1990 |